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INTRODUCTION
We shall discuss here the potential of proteomics (which defines the amino acid
sequence of all proteins expressed by a specific cell type under specific growth
conditions) and biomarker discovery, for diagnosis of inherited diseases (or cancer) and
non-culture based biodetection of infectious diseases (in clinical samples) or
environmental monitoring. Many of the instrumental developments in proteomics have
come from the field of analytical chemistry. Thus the work is highly relevant to all with
an interest in biomedical science, biology or chemistry. However since our research is
particularly focused on bacteriology, emphasis will be placed here in the microbiology
arena. Also recognizing that the audience of JSCAS is multi-disciplinary (and that the
journal is read by administrators, researchers and teachers (including professors and their
undergraduate or graduate students) I shall make no apologies that wherever possible I
shall provide brief explanations of the principles behind technical terms.
The US Market for molecular infectious disease diagnostic technology is predicted to
be approaching $4 billion in 2010 (http://www.clpmag.com/issues/articles/20071108.asp). The market for protein biomarker discovery was $290 million in 2005 which
is predicted to rise to $745 million in 2011 (Biobusiness, Biomarket Trends
(genengnews.com, March 1 2007). While proteomics has great potential for the US and
worldwide, as noted below, there are particular opportunities for SC. The bases of these
developments are the independent revolutions that have occurred in the fields of
molecular biology and analytical chemistry leading to the current inter-relatedness of
genomics, proteomics and bioinformatics.
The molecular biology revolution included the development of cloning, the
polymerase chain reaction (PCR) and use of restriction enzymes for recognition of
sequence differences among organisms employing genetic markers. Indeed in 1993,
Kary B. Mullis, received the Nobel Prize in Chemistry for the discovery of PCR. Dr.
Mullis went to high school in Columbia; so SC has a history in this area. The process of
marker discovery has been greatly aided in recent years by whole genome sequencing
(i.e. determining the entire genetic or DNA code for an organism) also allowing a more
systematic approach to biomarker discovery. While it is well known that the human
genome has been sequenced and annotated, it should also be emphasized that the
genomes of many common mammalian and other multi-cellular (eukaryotic) species and
single celled organisms (including most common human pathogens) have also been
sequenced. What used to take large groups of investigators months or years (and millions
of dollars) can now be accomplished in days or weeks (depending on the size of the
genome) at a fraction of the cost; although it is still expensive.

DNA AND PROTEIN MARKERS
It is anticipated the automated instrumental identification of peptide markers for
human pathogens will be considerably less labor-intensive than current DNA-based
approaches. Discovery of DNA markers e.g. using PCR involves: a. first defining
putative sequences from the genome; b. next primers (DNA sequences that are
complementary and recognize these sequences) are designed; c. PCR is tested with
relevant clinical samples; d. off-line sequencing of PCR product is often performed to
confirm identity in initial set-up experiments. In the case of protein markers a. (PCR) and
b. (primer design) are not required and d. (sequencing) is performed on-line as part of the
proteomic analysis. In other words there is only one instrumental marker
discovery/analysis step in a proteomics-based approach. Genetic or protein markers for
inherited diseases or cancer are determined in a similar fashion (markers discerning
diseased versus normal cells).
At USC we are focusing our efforts on basic research in marker discovery (with
support from the Sloan Foundation). However we also are extrapolating these concepts to
helping assess the utility of automated instrumentation developed by Virgin instruments
LLC (Boston, MA). Prototypes will be evaluated and modifications suggested for
specific applications by Automated Methods LLC, Columbia, SC. Recent advances in
proteomics technology provide accurate molecular weight (M.W.) and sequence
information on peptides from protein digests with high speed and sensitivity. These
advances include new mass spectrometers developed at Virgin together with more
efficient methods for interfacing separations with mass spectrometry with microbial
biomarker methodology developed at USC These systems provide practical solutions to
the problems that have severely limited the applications of proteomics for clinical
analyses. The focus of current R & D is on reproducibly detecting, identifying, and
quantifying human and microbial biomarkers in: 1) plasma, serum, urine and other body
fluids in the important 1 pg/mL to 1 ng/mL range and 2) environmental samples (e.g.
with biodefense and homeland security applications). This new family of instruments
employs 5 khz lasers providing data acquisition 25 times faster than any existing
commercial mass spectrometer.
Microbiological applications will be used to give an example of the applicability of
the technology. However, as noted above markers can be derived from any form of life
(e.g. human, bacterium, parasite or virus). Bacterial species share specific genes (and
encoded proteins) of characteristic sequence distinguishing them from other bacterial
species. Differences in DNA sequence are generally detected by real-time PCR. Since
the differences are small for closely related species; direct (automated Sanger
sequencing) or indirect approaches (e.g. restriction digestion) are often used to detect
these sequence variants.
Many forms of mass spectrometry have been successfully employed for identification
of cultured microorganisms, but none of these approaches provide the sensitivity,
specificity, simplicity and speed required for automated clinical identification or
detection of infectious agents in human body fluids without culture which is a work in
progress.
MARKER DISCOVERY
Discovery of useful biomarkers by the proposed methods requires two steps. First,
fractionation, separation, and analysis protocols must be optimized for potential

biomarkers for particular strains and species to be detected at clinically relevant level in
body fluids without culture. Second, peptides produced by digestion of proteins from
cultured organisms must be identified and their MS-MS (tandem mass spectrometry)
spectra recorded, interpreted, and stored in a searchable database together with all
available information including the source, strain and species of the organism. This
protocol must be sufficiently rapid, robust, and simple to allow its use in a clinical
setting. Thus, while limited separation and fractionation may be sufficient for the initial
discovery phase, it is important to establish a protocol using proteins from the cultured
samples that can be extended to reliable detection of these potential biomarkers at low
levels in body fluids. The ultimate goal is detection of specific biomarkers for previously
characterized pathogens, at clinically relevant concentrations, within one hour after
receipt of a body fluid and to characterize fluids containing previously unknown or
emerging pathogens within 48 hours.
Successful completion of this work may revolutionize clinical microbiology allowing
laboratory diagnosis in real-time (with equivalent sensitivity to PCR) but also real-time
identification of protein sequence variants. This could totally change the way that
treatment of infectious diseases is performed in the US. The instruments would also
revolutionize battlefield biodetection and counter-terrorism efforts for biological warfare
agents (e.g. anthrax). Instrumentation might be purchased by every hospital and/or first
responder (urban/battlefield) in the US. Each instrument, depending on sales, would be
in the $200,000- one million range. Ancillary products will include disposable reagents,
operator training, and up-datable data-bases of markers.
There has been a revolution in mass spectrometry leading to sequencing of the
expressed protein products of genomes (proteomics). Indeed the 2002 Nobel Prize in
Chemistry was awarded to Koichi Tanaka and John B. Fenn for their development
respectively of matrix assisted time of flight ionization/desorption (MALDI) and
electrospray ionization (ESI) mass spectrometry (MS). In both cases large molecules
(including proteins and DNA) are analyzed in native form from aqueous solutions in a
mass spectrometer. Scientists, whose research does not focus on mass spectrometers, are
often thinking of an older technology (gas chromatography-mass spectrometry [GCMS]). GC-MS (and more advanced GC-MS-MS) requires extensive chemical work-up to
convert a marker (usually a small molecule such a fatty acid) into a suitable form for
analysis in the gas phase. Indeed in the clinical microbiology field GC is now routinely
used in reference laboratories for whole cell fatty acid profiling after prior growth in
culture media (after conversion to FAMES, fatty acid methyl esters]). GC-MS provides
additional structure information on these profiles.
Microbiologists are often not well versed in performing organic chemical reaction
schemes and thus fatty acid profiling is limited to laboratories with an emphasis on
microbial biochemistry. However fatty acid profiling is still considered a gold standard in
taxonomy and classification and widely used in reference laboratories. There are also
several companies that will provide a fatty acid profile for a fee (e.g. MIDI Inc., Newark,
DE). Sample preparation for fatty acid analysis takes several hours. By comparison a
recent proteomics method for identification of Bacillus anthracis developed at US takes a
few minutes. The difference in time taken for the two analyses (hours versus minutes)
provides a perspective on how things have changed and potential for the future.

Additionally the presence or absence of a fatty acid monomer provides considerably less
specificity than a peptide sequence.
Alternatively, the genomic revolution has given us a vast array of molecular biology
tools for discrimination of well-known pathogens as well as emerging infections by the
presence or absence of genes or for closely related organisms, small changes in DNA
sequence. It is anticipated that protein-sequence based discrimination will be as important
for the next generation of clinical microbiologists and biomedical researchers.
In the newer so-called soft ionization MS technology, introduced in the 1990s and
2000s, biomolecules are analyzed without any separation of components or after
separation employing high performance liquid chromatography (LC) or electrophoresis.
This is performed in the liquid phase which is often aqueous in nature. Small molecules
can be analyzed but the real power of the technique is in being amenable to analysis of
larger molecules (e.g. peptides/proteins) without chemical pre-treatment.
For the non-mass spectrometrist, it should be pointed out that nowadays the analysis
of these large molecules is primarily based on MALDI MS or ESI MS. In the former
case, the sample is spotted, with a matrix, on a metal plate and allowed to air dry. When
struck with a laser beam, after the plate is inserted into the MS, the matrix absorbs the
light, transferring it to the molecule of interest (e.g. proteins or peptides). Generally, only
a singly ionized species is produced having a single charge. In contrast, ESI MS is
performed in solution and the sample is sprayed into the MS using a syringe pump. As
the droplets evaporate, charges are transferred to molecules present within the droplet.
Ions are produced that can have multiple charge states. Since mass analyzers generally
separate by the mass-to-charge ratio, simple spectra are generated for MALDI (molecules
having only one charge) but ESI spectra (reflecting mixtures of molecules each having
one, few or multiple charges) are more complex. Thus MALDI MS has been more
popular with biologists and biomedical researchers because of the simplicity of the
spectra. However ESI MS often allows the analysis of larger molecules. An extensive
knowledge of chemistry, in performing MALDI or ESI MS, is not required since the
molecule is analyzed in its native form without chemical treatment. Indeed as mentioned
above, in certain applications it is not necessary to employ a separation stage (i.e. LC or
electrophoresis) and the sample can be analyzed directly in the MS with minimal sample
pre-treatment.
Another independent but equally important instrumental advance has been the
commercial introduction of the tandem mass spectrometer (MS-MS, also in the 1990s2000s) allowing routine sequencing of peptides. Peptides are identified in two distinct
stages. First the molecular weight of the peptide is determined; they are volatilized in the
MS as intact molecules. Then, for MS-MS analysis, the peptides are broken into a series
of constituent mixture of peptides by breaking them at each peptide bond in the chain.
For example, in the following illustration purposely simplified for clarity: a tri-peptide AC-D (alanine-cysteine-aspartate) in sequence might generate alanine and cysteineaspartate on MS-MS analysis. The observation of a mass equivalent to A suggests that
alanine is the terminal amino acid. This is confirmed by the difference in mass between
ACD and CD suggesting that CD make up amino acids 2, 3 of the peptide. The finding of
a dipeptide of mass of AC suggests C is linked to A., i.e. is at position 2. The sequence is
thus A-C-D. Generally the analysis is more complex (and the spectra more difficult to

interpret) since the molecules are larger (usually 10-30 mers) and fragmentation is more
complex.
PROTEIN PROFILING
Direct extraction of bacterial vegetative cells or spores followed by MALDI MS
analysis has become popular for bacterial identification, since it is simple to perform and
mass spectra are readily interpreted. However, only high abundance peptides that are of
low mass and ionize readily are observed (e.g. 2-10,000 mass range). Generally the
spectra are plotted as the amount of each protein present (as defined by its molecular
weight, MW); Unfortunately MW alone is not sufficient to identify a characteristic
biomarker and one must rely on the entire spectrum, this often referred to as mass
profiling or fingerprinting. These spectral comparisons can be made by eye-balling but
generally pattern recognition-based computer programs are employed; unfortunately
there is often considerable variability in the spectra from run-to-run or between samples
complicating data interpretation.
Alternatively the sequences of individual proteins can be determined using MS-MS.
The presence of an individual marker can be determined with great confidence and one
does not have to depend on the consistency of the mass profile which can sometimes be
problematic. For example, in our recent work, the MWs of small acid soluble proteins
(SASPs) were measured using MALDI MS and confirmed by ESI MS. ESI-MS-MS
analysis was employed for the generation of sequence-specific information. The analysis
consists of simply extracting the samples and analyzing the extract directly into the MSMS instrument. ESI-MS revealed a prominent doublet of SASPs for all strains in these
studies. The first SASP varied in mass and sequence between B. anthracis versus B.
cereus/B. thuringiensis. The second SASP had the same MW for all strains correlating
with species (or clade; there are two for B. cereus) and served as an internal standard
allowing comparison between mass spectra in this study and previous ones. The entire
sample extraction and analysis takes under 10 min.
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PROTEOMICS
It should be emphasized protein profiling is distinct from classical proteomics based
approaches which involve more time-consuming sample processing. Proteomics often
employs 2D gel electrophoresis to isolate individual protein spots which are then digested
in situ, usually with trypsin, to generate peptides of characteristic masses that are
subsequently analyzed using MALDI MS analysis. The sequences of each peptide in the
tryptic digest can then be identified by MALDI MS-MS analysis. Alternatively, after
tryptic digestion of whole cells, the mixture of peptides is subjected to on-line liquid LCESI-MS-MS analysis (either one or two dimensional). In either case, separation
(electrophoresis or chromatography respectively) is important in reducing the complexity
of mixtures for analysis by the mass spectrometer but increases the learning curve in
implementing the MS technology for routine applications.
Proteomics is quite time consuming and technically demanding and is best used for
comparing the relatedness of two strains or species (or cancer versus normal cells).
Bioinformatics can be used to relate identified peptides to those predicted to be present in
proteins coded by whole genomes. In theory, a novel strain could be categorized in this
fashion. This requires bioinformatics analysis of multiple strains of each pair or group of
organisms to be discriminated which is complex and labor intensive. Alternatively LCMS-MS, or 2D-gel electrophoresis/MS-MS, could be used for the process of marker
discovery. Once the markers have been discovered, simple MS or MS-MS assays
(performed in aqueous solution) could be employed for routine analysis. The analogy is
the discovery of DNA markers by whole genomic comparison followed by real-time PCR
for diagnostic applications.
Sensitivity and specificity are both of particular importance; in trace detection of
microbial markers in complex biological matrices such as infected body fluids or tissues.
Indeed there is usually a separation (e.g. LC for proteins) or PCR amplification of the
target (DNA) marker in clinical diagnosis. In both instances this serves to increase the
concentration of the marker relative to background derived from other components of the
matrix, this simplifies the analysis.
Real-time PCR is the current leading non-culture-based technology for determination
of infection. More discriminating PCR-MS (mass spectrometry) for bacterial DNA
markers was developed in the US through collaboration between the University of South
Carolina and Pacific Northwest National Laboratory. In this case the mass accuracy is
sufficient to discriminate two PCR products differing by a single nucleotide substitution
(e.g. adenine to thymine [9 mass units] or guanine to cytosine [40 mass units]). An
automated commercial PCR-MS instrument was subsequently introduced by Ibis
Biosciences Inc., Carlsbad, CA based on these principles. PCR-MS has several
additional stages, versus PCR, including post-PCR sample clean-up and robotic transfer
from PCR to MS module. Thus PCR-MS is currently performed as a reference
laboratory technique. For example, it has been successfully used for determining
nucleotide composition, for strain typing in epidemiological studies of outbreaks of
respiratory infections with Streptococcus, Hemophilus or Neisseria.
CONCLUDING REMARKS
Once simple automated instruments are widely available, diagnosis of disease
variants or bacterial infection using protein markers will involve minimal sample
preparation and would be complementary (but simpler to perform) than widely used
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molecular biology approaches that often involve multiple sample processing steps (e.g.
PCR/off-line sequencing). However, the use of mass spectrometers is still daunting to
many in the microbiological, biological and biomedical communities. Hopefully this
review will contribute to removing some of the mystery behind what is ultimately a
simple tool that is highly amenable to unattended sample preparation and computer-based
decision making. Genomics is reaching maturity but high-through-put proteomics still
has great potential for growth. SC has an opportunity to not only benefit from these
developments but to be ahead of the curve and indeed lead them in the US to fruition.
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